Drugs /

recombinant interleukin-2

Back to Drugs List

Overview

NCI Definition [1]:
Any recombinant analog of endogenous interleukin-2 (IL-2), a cytokine involved in intercellular communication related to cell differentiation, proliferation, inflammation, hematopoiesis, neuronal functions, and release of hormones. IL-2 binds to and activates specific receptors, triggering expression of specific genes, and may induce T cell-mediated tumor regression in some tumor types.

Clinical Trials

View Clinical Trials for recombinant interleukin-2

Recombinant interleukin-2 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating recombinant interleukin-2, 1 is phase 1 (1 open).

MAGEA4 Expression and MAGEA8 Expression are the most frequent biomarker inclusion criteria for recombinant interleukin-2 clinical trials.

Malignant solid tumor is the most common disease being investigated in recombinant interleukin-2 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Recombinant Interleukin-2
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating recombinant interleukin-2 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ro-23-6019, ro236019, t-cell growth factor, mitogenic factor, recombinant interleukin-2, ro 23 6019, interleukin-2, lymphocyte mitogenic factor, il-2, interleukin-2, ro 236019, interleukin ii, thymocyte stimulating factor, ro-236019, tsf, tcgf
Drug Target(s) [2]:
IL2RA, IL2RB, IL2RG
NCIT ID [1]:
C587

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.